Target Information

Target General Infomation
Target ID
T17852
Former ID
TTDI02148
Target Name
Phosphodiesterase (PDE) 9
Gene Name
PDE9A
Synonyms
High affinity cGMPspecific 3',5'cyclic phosphodiesterase 9A; PDE9A
Target Type
Clinical Trial
Disease Alzheimer disease [ICD9: 331; ICD10: G30]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Genitourinary disease [ICD10: N00-N99]
Psychiatric disorder [ICD9: 290-319; ICD10: F01-F99]
Function
Hydrolyzes the second messengercGMP, which is a key regulator of many important physiological processes. {ECO:0000269|PubMed:18757755}.
BioChemical Class
Phosphoric diester hydrolases
UniProt ID
O76083
EC Number
EC 3.1.4.35
Sequence
MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTTISLLTTDDAM
VSIDPTMPANSERTPYKVRPVAIKQLSAGVEDKRTTSRGQSAERPLRDRRVVGLEQPRRE
GAFESGQVEPRPREPQGCYQEGQRIPPEREELIQSVLAQVAEQFSRAFKINELKAEVANH
LAVLEKRVELEGLKVVEIEKCKSDIKKMREELAARSSRTNCPCKYSFLDNHKKLTPRRDV
PTYPKYLLSPETIEALRKPTFDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLF
CVHDNYRNNPFHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYN
NTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFKQIRQGMITLI
LATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKCCDISNEVRPMEVAEPWVDCL
LEEYFMQSDREKSEGLPVAPFMDRDKVTKATAQIGFIKFVLIPMFETVTKLFPMVEEIML
QPLWESRDRYEELKRIDDAMKELQKKTDSLTSGATEKSRERSRDVKNSEGDCA
Drugs and Mode of Action
Drug(s) ASP-4901 Drug Info Phase 2 Genitourinary disease [524602]
BI-409306 Drug Info Phase 2 Psychiatric disorder [524914]
PF-4447943 Drug Info Phase 2 Alzheimer disease [522709]
Inhibitor ASP-4901 Drug Info [549161]
BI-409306 Drug Info [551883]
PF-04447943 Drug Info [543409]
PF-4181366 Drug Info [543409]
PF-4447943 Drug Info [532766]
SCH51866 Drug Info [534647]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Purine metabolism
Pathway Interaction Database Regulation of Androgen receptor activity
Reactome cGMP effects
References
Ref 522709ClinicalTrials.gov (NCT00930059) A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 524602ClinicalTrials.gov (NCT02038868) A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia. U.S. National Institutes of Health.
Ref 524914ClinicalTrials.gov (NCT02240693) Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo. U.S. National Institutes of Health.
Ref 532766A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.
Ref 534647Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998 Jun 19;273(25):15559-64.
Ref 543409(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309).
Ref 549161Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070)
Ref 551883Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.